Explore the latest advancements in global biosimilar access, including new treatments, strategic partnerships, and competitive market entries enhancing patient care.

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular ...

Biosimilar approvals surge in the US and Europe, enhancing access to denosumab and aflibercept therapies while driving significant health care savings.

Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...

Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars ...

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings. Patients with inflammatory bowel disease (IBD) who transitioned from ...

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates. Patients with ankylosing spondylitis ...

Biosimilars have delivered substantial cost savings and broadened patient access across Europe. However, stakeholders now face the growing risk of a “biosimilar void”—a scenario in which 90% of the ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults. Infliximab biosimilar ...